{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:57:04Z","timestamp":1790791024878,"version":"4.1.0"},"reference-count":29,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n \n Young children with exposure to or infection with\n Mycobacterium tuberculosis<\/jats:italic>\n are at high risk of developing tuberculosis disease, and postexposure tuberculosis preventive treatment decreases this risk. Evidence is limited regarding the dosing and safety of the 12-dose once-weekly rifapentine and isoniazid regimen (3HP) for tuberculosis preventive treatment in children younger than 2 years and in children living with HIV.\n <\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n This protocol describes Tuberculosis Trials Consortium (TBTC) Study 35, which aims to establish practical age- and weight-banded rifapentine doses for 3HP in children aged 0 to 12 years, including children younger than 2 years, and children living with HIV, while assessing safety, tolerability, palatability, and acceptability.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n TBTC Study 35 was a phase I\/II, open-label, multisite, single-arm, exposure-controlled dose-finding and safety study of 3HP in children aged 0 to 12 years, including children living with HIV. Novel water-dispersible rifapentine and isoniazid formulations were used. Building on TBTC Study 26 data, initial rifapentine doses were selected, and nonlinear mixed-effects modeling was used to analyze the pharmacokinetic data and evaluate subsequent rifapentine doses. Safety was monitored throughout the 12-week treatment period and 12-week posttreatment follow-up.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Data collection began with the first recruitment in November 2019. The last participant was enrolled in December 2023, and participant follow-up and data collection were completed in May 2024. As of now, 69 participants were enrolled. The trial was funded throughout this time period. Data analysis is ongoing, and trial results are expected to be disseminated in 2026.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n TBTC Study 35 is expected to provide pharmacokinetic and safety data to inform practical pediatric 3HP dosing recommendations, including for children younger than 2 years and children living with HIV.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/103274","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T08:10:05Z","timestamp":1787818205000},"page":"e103274-e103274","source":"Crossref","is-referenced-by-count":0,"title":["Dosing and Safety of Once-Weekly Rifapentine and Isoniazid for 12 Weeks for Tuberculosis Preventive Therapy in Children With and Without HIV: Protocol for a Phase I\/II Open-Label, Exposure-Controlled, Dose-Finding, and Safety Study (Tuberculosis Trials Consortium Study 35)"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-1035-3202","authenticated-orcid":false,"given":"Ingrid","family":"Courtney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9683-9630","authenticated-orcid":false,"given":"Meredith G","family":"Dixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3584-7477","authenticated-orcid":false,"given":"Louvina","family":"van der Laan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3093-9081","authenticated-orcid":false,"given":"Rada","family":"Savic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4621-5480","authenticated-orcid":false,"given":"Belen","family":"Solans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9013-5256","authenticated-orcid":false,"given":"Kelly","family":"Dooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2095-3576","authenticated-orcid":false,"given":"Deron","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4819-9501","authenticated-orcid":false,"given":"Shaun","family":"Barnabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9437-776X","authenticated-orcid":false,"given":"Avy","family":"Violari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0785-7800","authenticated-orcid":false,"given":"Kia","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5444-450X","authenticated-orcid":false,"given":"Nigel","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-7024","authenticated-orcid":false,"given":"Patrick","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3232-0546","authenticated-orcid":false,"given":"Erin","family":"Sizemore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8716-7107","authenticated-orcid":false,"given":"Wendy","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9629-5952","authenticated-orcid":false,"given":"Susan","family":"Purchase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7362-9962","authenticated-orcid":false,"given":"Elri","family":"Nortier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6144-4989","authenticated-orcid":false,"given":"Joh-Nell","family":"van der Westhuizen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0116-9013","authenticated-orcid":false,"given":"Anne-Marie","family":"Demers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9399-9834","authenticated-orcid":false,"given":"Anneke","family":"Hesseling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8057-4391","authenticated-orcid":false,"given":"Rosanna","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"key":"R1","unstructured":"World Health Statistics 2024: Monitoring Health for the SDGs, Sustainable Development Goals. World Health Organization; 2024. URL: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/74b12494-f213-4b5b-9533-18442147e1fb\/content [Accessed 02-09-2026]"},{"issue":"4","key":"R2","first-page":"392","volume":"8","author":"Marais","journal-title":"Int J Tuberc Lung Dis"},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-13-392","article-title":"Risk factors for infection and disease in child contacts of multidrug-resistant tuberculosis: a cross-sectional study","volume":"13","author":"Seddon","journal-title":"BMC Infect Dis"},{"issue":"10228","key":"R4","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/S0140-6736(20)30166-5","article-title":"The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis","volume":"395","author":"Martinez","journal-title":"Lancet"},{"issue":"3","key":"R5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1473-3099(16)30474-1","article-title":"Mortality in children diagnosed with tuberculosis: a systematic review and meta-analysis","volume":"17","author":"Jenkins","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"R6","first-page":"650","volume":"14","author":"Van Wyk","journal-title":"Int J Tuberc Lung Dis"},{"issue":"1","key":"R7","first-page":"13","volume":"10","author":"van Zyl","journal-title":"Int J Tuberc Lung Dis"},{"key":"R8","unstructured":"3.3.5. Options for TB preventive treatment regimens: drug-susceptible TB. WHO TB Knowledge Sharing. 2025. URL: https:\/\/tbksp.who.int\/en\/node\/2065 [Accessed 03-08-2025]"},{"issue":"6 Pt 1","key":"R9","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1164\/ajrccm\/148.6_Pt_1.1541","article-title":"Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice","volume":"148","author":"Ji","journal-title":"Am Rev Respir Dis"},{"issue":"23","key":"R10","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","journal-title":"N Engl J Med"},{"issue":"3","key":"R11","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/jamapediatrics.2014.3158","article-title":"Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid","volume":"169","author":"Villarino","journal-title":"JAMA Pediatr"},{"issue":"4","key":"R12","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1093\/jac\/dkaf029","article-title":"Pharmacokinetics and safety of rifapentine in children: dosing for latent tuberculosis infection","volume":"80","author":"Liu","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"R13","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/jpids\/pit077","article-title":"Rifapentine pharmacokinetics and tolerability in children and adults treated once weekly with rifapentine and isoniazid for latent tuberculosis infection","volume":"3","author":"Weiner","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"2","key":"R14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.5588\/ijtld.12.0641","article-title":"Twice-weekly therapy for children with tuberculosis infection or exposure","volume":"17","author":"Cruz","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"R15","doi-asserted-by":"publisher","first-page":"e401","DOI":"10.1016\/S2352-3018(20)30032-1","article-title":"Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1\/2 trial","volume":"7","author":"Dooley","journal-title":"Lancet HIV"},{"issue":"1","key":"R16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/cid\/ciab908","article-title":"Optimizing dosing and fixed-dose combinations of rifampicin, isoniazid, and pyrazinamide in pediatric patients with tuberculosis: a prospective population pharmacokinetic study","volume":"75","author":"Denti","journal-title":"Clin Infect Dis"},{"issue":"10","key":"R17","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1093\/cid\/ciab725","article-title":"Pharmacokinetics of first-line drugs in children with tuberculosis, using World Health Organization\u2013recommended weight band doses and formulations","volume":"74","author":"Chabala","journal-title":"Clin Infect Dis"},{"issue":"9","key":"R18","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1093\/cid\/ciab665","article-title":"Pharmacokinetics and safety of 3 months of weekly rifapentine and isoniazid for tuberculosis prevention in pregnant women","volume":"74","author":"Mathad","journal-title":"Clin Infect Dis"},{"issue":"6","key":"R19","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1128\/AAC.01918-13","article-title":"Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability","volume":"58","author":"Savic","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"R20","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1164\/rccm.200311-1612OC","article-title":"Pharmacokinetics of rifapentine at 600, 900, and 1,200 mg during once-weekly tuberculosis therapy","volume":"169","author":"Weiner","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"R21","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.24","article-title":"Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose","volume":"2","author":"Keizer","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"5","key":"R22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/01.inf.0000214963.55217.9c","article-title":"Pharmacokinetics of rifapentine in children","volume":"25","author":"Blake","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"R23","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology--drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","journal-title":"N Engl J Med"},{"issue":"1","key":"R24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","article-title":"Mechanism-based concepts of size and maturity in pharmacokinetics","volume":"48","author":"Anderson","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"R25","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2133\/dmpk.24.25","article-title":"Mechanistic basis of using body size and maturation to predict clearance in humans","volume":"24","author":"Anderson","journal-title":"Drug Metab Pharmacokinet"},{"issue":"11","key":"R26","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s40262-015-0277-z","article-title":"Prediction of fat-free mass in children","volume":"54","author":"Al-Sallami","journal-title":"Clin Pharmacokinet"},{"key":"R27","unstructured":"Karlsson M Holford N . A tutorial on visual predictive checks [Poster]. Presented at: Population Approach Group in Europe (PAGE); Jun 18-20, 2008; Marseille, France. URL: https:\/\/www.page-meeting.org\/wp-content\/uploads\/pdf_abstracts\/8694-Karlsson_Holford_VPC_Tutorial_hires.pdf [Accessed 02-09-2026]"},{"key":"R28","unstructured":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. World Health Organization; 2018. URL: https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/d68456c8-2a25-419b-83eb-1dc9df1b838f\/content [Accessed 02-09-2026]"},{"key":"R29","unstructured":"Clayden P . Dolutegravir can be given with 3HP to prevent TB without dose adjustment. HIV i-Base. 2019. URL: https:\/\/i-base.info\/htb\/35823 [Accessed 02-09-2026]"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:16:17Z","timestamp":1790788577000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e103274"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":29,"URL":"https:\/\/doi.org\/10.2196\/103274","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,30]]},"article-number":"v15i4e103274"}}